Despite the tremendous advancements in insulin delivery modes that have occurred over the last few decades, life expectancy is still lower in individuals with T1DM than in the general population.19 As a result, clinical trials targeting innate and adaptative immunity (both T and B cells) to modify the natural course of T1DM have continued to garner attention. Here, INS is linked to type 1 diabetes mellitus.